Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smyth

Showing results (281-290 of 294) with videos related to

Pageof 30
Sort By:
Lancet (London, England)|October 19, 1985
Malignant melanoma in Scotland 1979-1983R M MacKie, J F Smyth, D S Soutar, et al.
The Journal of Clinical Investigation|September 11, 2009
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humansKellie A Charles, Hagen Kulbe, Robin Soper, et al.
Seminars in Oncology|September 1, 1984
Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative studyJ F Smyth, M A Cornbleet, R C Stuart-Harris, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1984
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patientsM A Cornbleet, R C Stuart-Harris, I E Smith, et al.
British Medical Journal|December 4, 1976
Intensive investigation in management of Hodgkin's diseaseS B Sutcliffe, P F Wrigley, J F Smyth, et al.
Cancer Research|December 26, 2003
Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppressionEuan A Stronach, Grant C Sellar, Cherie Blenkiron, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 30, 1998
Estrogen regulation of transforming growth factor-alpha in ovarian cancerB J Simpson, S P Langdon, G J Rabiasz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2010
WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosisAdam J W Paige, Manuela Zucknick, Szymon Janczar, et al.
British Journal of Cancer|February 1, 1996
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancerJ M Bartlett, S P Langdon, B J Simpson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerE R Brown, K A Charles, S A Hoare, et al.
Pageof 30

Showing results (281-290 of 294) with videos related to

Sort By:
Pageof 30
Lancet (London, England)|October 19, 1985
Malignant melanoma in Scotland 1979-1983R M MacKie, J F Smyth, D S Soutar, et al.
The Journal of Clinical Investigation|September 11, 2009
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humansKellie A Charles, Hagen Kulbe, Robin Soper, et al.
Seminars in Oncology|September 1, 1984
Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative studyJ F Smyth, M A Cornbleet, R C Stuart-Harris, et al.
European Journal of Cancer & Clinical Oncology|September 1, 1984
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patientsM A Cornbleet, R C Stuart-Harris, I E Smith, et al.
British Medical Journal|December 4, 1976
Intensive investigation in management of Hodgkin's diseaseS B Sutcliffe, P F Wrigley, J F Smyth, et al.
Cancer Research|December 26, 2003
Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppressionEuan A Stronach, Grant C Sellar, Cherie Blenkiron, et al.
The Journal of Steroid Biochemistry and Molecular Biology|May 30, 1998
Estrogen regulation of transforming growth factor-alpha in ovarian cancerB J Simpson, S P Langdon, G J Rabiasz, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2010
WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosisAdam J W Paige, Manuela Zucknick, Szymon Janczar, et al.
British Journal of Cancer|February 1, 1996
The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancerJ M Bartlett, S P Langdon, B J Simpson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2008
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancerE R Brown, K A Charles, S A Hoare, et al.
Pageof 30